{"id":"betrixaban","rwe":[],"tags":[{"label":"Factor Xa Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Coagulation factor X","category":"target"},{"label":"F10","category":"gene"},{"label":"KCNH2","category":"gene"},{"label":"F2","category":"gene"},{"label":"B01AF04","category":"atc"},{"label":"LOE Approaching","category":"status"},{"label":"At risk of venous thromboembolus","category":"indication"},{"label":"Portola Pharms Inc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Antithrombins","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Factor Xa Inhibitors","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"},{"label":"Serine Proteinase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Portola Pharms Inc","patents":[{"applNo":"N208383","source":"FDA Orange Book","status":"Active","expires":"Sep 8, 2028","useCode":"U-1167","territory":"US","drugProduct":false,"patentNumber":"8557852","drugSubstance":false},{"applNo":"N208383","source":"FDA Orange Book","status":"Active","expires":"Nov 7, 2026","useCode":"U-1502","territory":"US","drugProduct":false,"patentNumber":"9555023","drugSubstance":false},{"applNo":"N208383","source":"FDA Orange Book","status":"Active","expires":"Mar 29, 2031","useCode":"U-2034","territory":"US","drugProduct":true,"patentNumber":"8404724","drugSubstance":false},{"applNo":"N208383","source":"FDA Orange Book","status":"Active","expires":"Dec 28, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8987463","drugSubstance":false},{"applNo":"N208383","source":"FDA Orange Book","status":"Active","expires":"Nov 8, 2026","useCode":"","territory":"US","drugProduct":false,"patentNumber":"7598276","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BETRIXABAN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:23:44.563208+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:23:44.563142+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:23:50.056845+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BETRIXABAN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:23:51.004802+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Coagulation factor X inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:52.033788+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL512351/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:51.700401+00:00"}},"allNames":"bevyxxa","offLabel":[],"synonyms":["betrixaban","PRT054021","betrixaban maleate","bevyxxa"],"timeline":[{"date":"2017-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PORTOLA PHARMA INC to Portola Pharms Inc"},{"date":"2017-06-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Portola Pharma Inc)"},{"date":"2026-11-08","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7598276 expires"}],"aiSummary":"Bevyxxa (Betrixaban) is a small molecule factor Xa inhibitor developed by Portola Pharma Inc, targeting coagulation factor X to prevent venous thromboembolism. It was FDA-approved in 2017 for patients at risk of venous thromboembolus. Bevyxxa is a patented medication with no generic manufacturers available. Key safety considerations include bleeding risks, which can be severe. As a factor Xa inhibitor, Bevyxxa works by blocking the action of factor Xa in the coagulation cascade.","brandName":"Bevyxxa","ecosystem":[{"indication":"At risk of venous thromboembolus","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Coagulation factor X","novelty":"Follow-on","targets":[{"gene":"F10","source":"DrugCentral","target":"Coagulation factor X","protein":"Coagulation factor X"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"F2","source":"DrugCentral","target":"Prothrombin","protein":"Prothrombin"}],"moaClass":"Factor Xa Inhibitors","modality":"Small Molecule","drugClass":"Factor Xa Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Bevyxxa selectively and reversibly inhibits factor Xa through a non-covalent binding interaction, thereby preventing the conversion of prothrombin to thrombin and ultimately inhibiting the coagulation cascade."},"commercial":{"launchDate":"2017","_launchSource":"DrugCentral (FDA 2017-06-23, PORTOLA PHARMA INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5241","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BETRIXABAN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BETRIXABAN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:59:15.547042","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:53.219762+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"rivaroxaban","drugSlug":"rivaroxaban","fdaApproval":"2011-07-01","patentExpiry":"Feb 17, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"apixaban","drugSlug":"apixaban","fdaApproval":"2012-12-28","patentExpiry":"Nov 22, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"edoxaban","drugSlug":"edoxaban","fdaApproval":"2015-01-08","patentExpiry":"Mar 28, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"betrixaban","indications":{"approved":[{"name":"At risk of venous thromboembolus","source":"DrugCentral","snomedId":427631000,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Portola Pharms Inc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"rivaroxaban","brandName":"rivaroxaban","genericName":"rivaroxaban","approvalYear":"2011","relationship":"same-class"},{"drugId":"apixaban","brandName":"apixaban","genericName":"apixaban","approvalYear":"2012","relationship":"same-class"},{"drugId":"edoxaban","brandName":"edoxaban","genericName":"edoxaban","approvalYear":"2015","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03728166","phase":"NA","title":"Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-02-01","conditions":["Venous Thromboembolism"],"enrollment":400,"completionDate":"2026-06-30"},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":["Atrial Fibrillation","Left Atrial Appendage Thrombosis","CVA"],"enrollment":0,"completionDate":"2024-07-11"},{"nctId":"NCT03346083","phase":"PHASE1","title":"Study Evaluating Betrixaban in Pediatric Participants","status":"TERMINATED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2018-07-13","conditions":["VTE Prophylaxis"],"enrollment":21,"completionDate":"2019-10-08"},{"nctId":"NCT00999336","phase":"PHASE1","title":"A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2009-07-31","conditions":["Renal Impairment"],"enrollment":32,"completionDate":"2010-02-28"},{"nctId":"NCT03330457","phase":"PHASE2","title":"A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing","status":"TERMINATED","sponsor":"Portola Pharmaceuticals","startDate":"2015-08-06","conditions":["Bleeding"],"enrollment":18,"completionDate":"2016-02-22"},{"nctId":"NCT01765868","phase":"PHASE1","title":"A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2007-09","conditions":["Healthy Subjects"],"enrollment":8,"completionDate":"2007-10"},{"nctId":"NCT02596100","phase":"PHASE1","title":"A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2015-09","conditions":["Healthy"],"enrollment":52,"completionDate":"2015-11"},{"nctId":"NCT01583218","phase":"PHASE3","title":"Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2012-03","conditions":["Venous Thromboembolism (VTE)"],"enrollment":7513,"completionDate":"2016-01"},{"nctId":"NCT00742859","phase":"PHASE2","title":"Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2008-10","conditions":["Atrial Fibrillation"],"enrollment":508,"completionDate":"2009-11"},{"nctId":"NCT01229254","phase":"PHASE2","title":"Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2010-09","conditions":["Atrial Fibrillation","Atrial Flutter"],"enrollment":189,"completionDate":"2011-04"},{"nctId":"NCT00375609","phase":"PHASE2","title":"Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2006-05","conditions":["Thromboembolism"],"enrollment":215,"completionDate":"2007-02"},{"nctId":"NCT01765855","phase":"PHASE1","title":"An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2007-09","conditions":["Health Volunteers"],"enrollment":5,"completionDate":"2007-10"},{"nctId":"NCT03613402","phase":"","title":"BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes","status":"WITHDRAWN","sponsor":"Portola Pharmaceuticals","startDate":"2018-09","conditions":["Venous Thromboses"],"enrollment":0,"completionDate":"2020-01"},{"nctId":"NCT03397888","phase":"PHASE1","title":"The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2017-11-16","conditions":["Hepatic Impairment"],"enrollment":32,"completionDate":"2018-01-16"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"258885","NDDF":"017262","UNII":"74RWP7W0J9","CHEBI":"CHEBI:140421","VANDF":"4036878","INN_ID":"8950","RXNORM":"1927851","UMLSCUI":"C2698385","chemblId":"CHEMBL512351","ChEMBL_ID":"CHEMBL512351","KEGG_DRUG":"D08873","DRUGBANK_ID":"DB12364","PUBCHEM_CID":"10275777","SNOMEDCT_US":"735227003","IUPHAR_LIGAND_ID":"9602","SECONDARY_CAS_RN":"936539-80-9","MESH_SUPPLEMENTAL_RECORD_UI":"C543086"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2017-","companyName":"Portola Pharma Inc","relationship":"Original Developer"},{"period":"present","companyName":"Portola Pharms Inc","relationship":"Current Owner"}],"publicationCount":226,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AF04","allCodes":["B01AF04"]},"biosimilarFilings":[],"originalDeveloper":"Portola Pharma Inc","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Portola Pharms Inc","companyId":"portola-pharms-inc","modality":"Small molecule","firstApprovalDate":"2017","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"refused","approval_date":null,"mah":null,"brand_name_local":"Dexxience","application_number":"EMEA/H/C/004309"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Dexxience","application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:23:53.219762+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}